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Abstract
Background: The global Choosing Wisely campaign has identified the following psychotropic prescribing as
low-value (harmful or wasteful): (1) benzodiazepine use in the elderly, (2) antipsychotic use in dementia and (3)
prescribing two or more antipsychotics concurrently. We aimed to quantify the extent of these prescribing
practices in the Australian population.
Methods: We applied indicators to dispensing claims of a 10% random sample of Australian Pharmaceutical
Benefits Scheme beneficiaries to quantify annual rates of each low-value practice from 2013 to 2016. We also
assessed patient factors and direct medicine costs (extrapolated to the entire Australian population) associated
with each practice in 2016.
Results: We observed little change in the rates of the three practices between 2013 and 2016. In 2016, 15.3%
of people aged ≥65 years were prescribed a benzodiazepine, 0.5% were prescribed antipsychotics in the context of
dementia and 0.2% of people aged ≥18 years received two or more antipsychotics concurrently. The likelihood of
elderly people receiving benzodiazepines or antipsychotics in the context of dementia increased with age and the
likelihood of receiving all three practices increased with comorbidity burden. In 2016, direct medicine costs to the
government of all three practices combined, extrapolated to national figures, were > $21 million AUD.
Conclusions: Our indicators suggest that the frequency of these three practices has not changed appreciably in recent
years and that they incur significant costs. Worryingly, people with the greatest risk of harm from these prescribing
practices are often the most likely to receive them.
Keywords: Elderly, Benzodiazepines, Antipsychotics, Dementia, Polypharmacy, Choosing wisely
Background
The conception of the global Choosing Wisely campaign
has heralded a renewed interest in addressing low-value
care; medical practices such as test ordering, procedures
or prescribing that are either harmful or wasteful [1]. The
Choosing Wisely campaign is a physician-led, grass-root
program which generates evidence-based ‘top 5 lists’ of
practices considered low-value across a breadth of medical
specialties [2, 3]. Choosing Wisely was conceived in the
U.S. in 2012 and has since spread globally across Europe
and Asia to over 20 countries around the world, launching
in Australia in April 2015 [4]. The campaign nominates
low-value practices to be focal points of conversations be-
tween patients and physicians with the ultimate aim of
promoting alternative, more appropriate care. Developing
indicators to quantify the extent of low-value medical
practices allows policy priorities to be set and any changes
following quality improvement strategies to be measured.
The majority of previous population-based research on
low-value care has focused on medical tests and proce-
dures [5], with limited attention to low-value prescribing
practices [6]. This is despite the fact that when the nomi-
nated low-value practices in each country participating in
the Choosing Wisely campaign are pooled, prescribing
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practices constitute nearly one quarter of all practices [6].
Of these, psychotropic prescribing practices feature heav-
ily, and while measuring inappropriate psychotropic use in
routinely collected data is not novel, examining them
through the lens of low-value care is a relatively recent
endeavor.
Most efforts to quantify low-value prescribing to date,
such as the Australian Atlas of Variation in Health Care
[7], have been based on aggregated dispensing claims
data. Within the constraints of data content, individual-
level analyses enhance measurement approaches by
allowing individuals receiving low-value prescribing
practices to be more accurately identified.
Our overall objective was to develop indicators that
can be applied to Pharmaceutical Benefits Scheme
(PBS) data to quantify three low-value psychotropic
prescribing practices in Australia. These practices
were chosen as they were mentioned repeatedly within
and between pooled national Choosing Wisely lists [6]
and were conducive to measurement approaches using
dispensing claims data. These practices are: (1) don’t
use benzodiazepines in the elderly, (2) avoid antipsy-
chotics for dementia and (3) don’t routinely prescribe
two or more antipsychotics concurrently. Specifically,
we applied indicators to estimate the annual rates of
these practices between 2013 and 2016 and their asso-
ciation with patient age, sex and co-morbidity. While
this may not capture changes resulting from the
launch of Choosing Wisely in Australia, it provides an
understanding of any underlying trends. We also esti-
mated the direct costs of the medicines involved in
each low-value psychotropic prescribing practice to
the Australian government and patients.
Methods
Study setting, data and population
Australia has a publicly funded universal healthcare
system entitling all citizens and permanent residents to
subsidised access to prescription medicines via the
Pharmaceutical Benefits Scheme (PBS). In this study, we
used PBS dispensing records from 2010 to 2016 for a
10% random sample of all persons eligible to receive
PBS-listed medicines. This is a standard dataset provided
by the Australian Government Department of Human
Services for analytical use and captures the majority of
community based medicine dispensing [8]. Our study
population consisted of all people 18 years and older
within the PBS 10% sample with at least one dispensing
record during the study period, 1 January 2013 through
31 December 2016.
Medicines of interest
We included medicines belonging to Anatomical Thera-
peutic Chemical Classification (ATC) classes antipsy-
chotics (NO5A), benzodiazepines (NO5BA, NO5CD and
NO3AE) and anti-dementia medicines (NO6D) [9] that
were PBS-subsidised in Australia during the study period
(see Additional file 1: Table S1 for full details of medi-
cines and ATC codes).
Indicators of low-value prescribing practices
Since some measures require specific clinical informa-
tion that is not contained within available dispensing
claims data, we developed primary and secondary indica-
tors for each low-value practice to illustrate the sensitiv-
ity of measurement to indicator definition (Table 1).
In this study, we defined annual incident (new) use as
a dispensing of a medicine in a given year with no dis-
pensings of that medicine in the 12months prior and
annual prevalent use as any dispensings of that medicine
in a given year. We defined concurrent use of two or
more antipsychotics (hereafter referred to as anti-
psychotic polypharmacy) as an overlap in antipsychotic
exposure of > 60 days; an intentionally conservative
measure that has been validated in dispensing claims
data [10, 11]. The duration of exposure following a
Table 1 Primary and secondary indicators applied to Pharmaceutical Benefits Scheme (PBS) dispensing claims data to measure each
low-value prescribing practice
Low-value practice Indicator
Primary Secondary Secondary indicator justification
Don’t use benzodiazepines in
the elderly
People ≥65 years with prevalent
benzodiazepine use
People ≥65 years with incident
(new) benzodiazepine use
New benzodiazepine use defines
a narrower population of recipients
of this practice than prevalent use
Avoid antipsychotics for dementia People ≥65 years dispensed an
anti-dementia medicine in the same
year or the three calendar years prior
to being dispensed an antipsychotica
People ≥65 years with incident
(new) antipsychotic use
Incident antipsychotic use is unlikely
to be for an indication where the
evidence of risk and benefit is clear
(schizophrenia or bipolar disorder)
Don’t routinely prescribe two or
more antipsychotics concurrently
People ≥18 years dispensed two or
more antipsychotics with overlapping
treatment exposures of 60 days
As for primary but excluding
long acting depot preparationsb
Concomitant use of a long acting
depot with an oral antipsychotic may
be necessary during initial stages of
therapy while dosing is being optimized
aAnti-dementia medicines are PBS subsidised for Alzheimer’s dementia but may be used in other forms of dementia in practice [34]
bLong acting depot preparations are identified in Additional file 1: Table S1
Brett et al. BMC Health Services Research         (2018) 18:1009 Page 2 of 8
single antipsychotic dispensing was estimated as the
time by which 75% of people had a repeat dispensing the
same antipsychotic as previously described [10].
Data analysis
Annual rates of low-value psychotropic prescribing (2013–
2016)
We applied each indicator to estimate the number of
persons experiencing the corresponding low-value prac-
tice in each calendar year. We divided this by the corre-
sponding mid-calendar year population estimates from
the Australian Bureau of Statistics (ABS) [12] for people
in the relevant age group to calculate the annual rates of
each prescribing practice.
We used different denominators to illustrate changes
from an indication perspective [13] and for our primary
indicators expressed antipsychotic use in the context of
dementia as a percentage of people with dementia (de-
fined as people with a prior anti-dementia medicine
dispensing) and antipsychotic polypharmacy as a per-
centage of people receiving any antipsychotic.
Patient factors associated with low-value prescribing
practices
For our primary indicators only, we stratified the
rates of each low-value practice in 2016 by patient
age, sex and comorbidity score. We categorised age at
the time of dispensing as 65–74, 75–84 and ≥ 85 years
for benzodiazepines in the elderly and antipsychotics
in the context of dementia and as 18–49, 50–64
and ≥ 65 years for antipsychotic polypharmacy. We es-
timated the number of comorbidities for each individ-
ual in the population dispensed any medicine with
the RxRisk score [14] using the 12 months of dispens-
ings prior to the first dispensing of any medicine in
2016. For each practice, we excluded comorbidities
from the RxRisk score that were part of the practice
to avoid inflating associations and categorised the
number of comorbidities as; 0–2, 3–5, 6–8, and ≥ 9.
To estimate the association of patient age, sex and co-
morbidity score with each low-value practice indicator
in 2016, we ran crude and adjusted logistic regression
analyses. We expressed associations as crude and ad-
justed odds ratios with 95% confidence intervals, using
males, the youngest age group and 0–2 comorbidities as
reference categories.
Direct medicine costs
For our primary indicators only, we calculated direct
medicine costs by identifying all dispensings associated
with each low-value practice in 2016. For antipsychotic
polypharmacy we summed the costs of all antipsychotics
involved in a polypharmacy episode, as we were not able
to determine appropriate monotherapy. We calculated
medicine costs to the Australian government and patients
based on co-payment thresholds and medicine cost at
the date of dispensing using historical data supplied
by the PBS Advisory Board. To obtain national cost
estimates we multiplied these estimates from the PBS
10% sample by ten.
All analyses were performed with SAS, version 9.4
(SAS Institute Inc) and Stata version 12 (Statacorp).
Results
According to our indicators, we found little to no
change in the annual rates of each low-value prescribing
practice across the study years. The rates of both pri-
mary and secondary indicators are shown in Fig. 1 but
henceforth we refer only to primary indicators. The rate
of prevalent use of benzodiazepines in the elderly (≥65
year olds) was 16.5% in 2013 and 15.3% in 2016. Anti-
psychotic use in the context of dementia in the elderly
was 0.4% in 2013 and 0.5% in 2016 and the rate of anti-
psychotic polypharmacy remained 0.2% throughout the
study period.
Among people with dementia, 24.9% received an anti-
psychotic in 2013 and 21.3% in 2016. Among people
who were dispensed an antipsychotic, 6.7% received
antipsychotic polypharmacy in 2013 and 7.1% in 2016
(Additional file 1: Figure S1a and b).
Patient factors associated with low-value psychotropic
prescribing
In 2016, based on primary indicators; elderly women
had greater adjusted odds than men of receiving benzo-
diazepines and the adjusted odds of receiving a benzodi-
azepine increased with patients’ age and number of
comorbidities (Fig. 2, Additional file 1: Table S2). The
adjusted odds of receiving an antipsychotic in the con-
text of dementia were independent of sex but increased
with age and comorbidity. The adjusted odds of receiv-
ing antipsychotic polypharmacy decreased with age and
increased with comorbidity (Fig. 2, Additional file 1: Tables
S2, S3 and S4 for adjusted and crude odds ratios as well as
stratified prevalence of each practice).
Based on the extrapolated costs of our primary indica-
tors, the direct medicine cost of benzodiazepine use in
the elderly in 2016 was $13.8 million to patients and
$12.2 million to the government; for antipsychotic use in
the context of dementia extrapolated costs were $0.7
million to patients and $2.1 million to the government;
and for antipsychotic polypharmacy costs were $0.5 mil-
lion to patients $5.3 million to the government
(Table 2).
Discussion
Here we developed indicators within PBS dispensing
claims to describe annual trends, associated patient factors
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and direct medicine costs of three low-value prescribing
practices as nominated by the Choosing Wisely campaign.
According to these indicators, there were no major
changes in the rate of any of these practices on a national
level over the study period. This is despite long-standing
evidence of the poor risk-benefit profiles of the practices
described [15–17] and multiple national and local clinical
interventions targeting these practices during this time
[18]. There may however have been changes in the rates
of these practices within smaller geographical areas that
we did not examine.
While it may be too early to detect a measurable im-
pact, according to our indicators, there has been no dis-
cernable change in the rates of these practices in
relation to the launch of the Choosing Wisely Australia
campaign in April 2015. However, only benzodiazepine
use in the elderly and antipsychotic use in dementia
were mentioned in the Choosing Wisely Australia cam-
paign [19] and the wording of these practices specified
indications and/or caveats. For instance the Australian
and New Zealand Society of Geriatric Medicine states
“do not prescribe benzodiazepines or other sedative-hyp-
notics to older adults as first choice for insomnia, agita-
tion or delirium” and “do not use antipsychotics as the
first choice to treat behavioral and psychological symp-
toms of dementia (BPSD)”. Despite this it is likely that
our measurement of benzodiazepine use in the elderly
closely approximates the Australian variant of this prac-
tice, as benzodiazepines make up almost all
sedative-hypnotic use in the elderly population. Further-
more, with the exceptions of epilepsy (clonazepam only)
and anxiety, there would be few other indications that
they would be used for in the elderly other than insom-
nia, agitation or delirium [20].
Caveats within these practices exemplify challenges in-
herent to measuring many Choosing Wisely recommen-
dations in routinely collected data and suggest that
quantification of these practices might not have been
considered when lists of low-value practices were being
constructed. For instance, it is difficult to determine
whether antipsychotics are being used as ‘first choice’ in
dementia when the preferred first choice is a
non-pharmaceutical intervention that is not recorded in
dispensing claims data. Similarly, don’t routinely pre-
scribe two or more antipsychotics concurrently also begs
the question of how frequent ‘routinely’ actually is and
on a clinical level this is open to inconsistent interpret-
ation. Here we quantify prescribing practices defined as
low-value a-priori by the Choosing Wisely campaign,
and while there may be clinical circumstances in which
such prescribing is appropriate we have taken these
practices at face value. Historically, a number of other
physician-led, consensus-based guidelines such as the
Beers and STOPP criteria [21, 22] have been developed
a
b
c
Fig. 1 Annual rate of low-value prescribing practice indicators: primary
(solid) and secondary (dash); a benzodiazepine use in the elderly
(primary = prevalent use, secondary = incident use) b antipsychotic use
in dementia (primary = past anti-dementia medicine, secondary =
incident antipsychotic use), c antipsychotic polypharmacy (primary = all
antipsychotic polypharmacy, secondary = antipsychotic polypharmacy
minus long acting depots)
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to identify potentially inappropriate prescribing practices
and assist with de-prescribing, but these tend to focus
on specific populations (such as the elderly).
Other measurement issues related to ascertainment
become apparent when comparing this study to U.S.
studies of antipsychotic use in dementia using Medi-
care data where dementia diagnoses from clinical en-
counter information are available. One such study
showed mean annual rates of antipsychotic use in
dementia to be higher (31%) than our study (21% in
2016), most likely because of more accurate demen-
tia ascertainment [23]. Another UK study found that
15.2% of elderly patients with dementia had received
an antipsychotic, but this study only included people
prescribed ‘low doses’ within one primary care trust
[24].
It is concerning, but not surprising, that the likeli-
hood of receiving the first two practices increases
with age, and the likelihood of receiving all three
practices increases with comorbidity burden, as this is
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Fig. 2 Adjusted odds ratios from multiple logistic regression analyses for patient factors associated with each low-value prescribing practice
in 2016
Table 2 Number of dispensings and extrapolated direct medicine costs of three low-value prescribing practices in 2016
Low-value prescribing practice
Benzodiazepines in elderly Antipsychotics in dementia Antipsychotic polypharmacy
Number of dispensings (in PBS 10% sample) 240,460 11,777 51,310
Extrapolated direct medicine costs (/$ million) Patients 13.8 0.7 0.5
Government 12.2 2.1 5.3
Total 26 2.8 5.8
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accompanied by a commensurate increase in the risk
of adverse events associated with frailty, polypharmacy
and drug-disease interactions [25]. Hence, caution is
required when prescribing antipsychotics in this clin-
ical context.
While the main focus of the Choosing Wisely cam-
paign is to promote safe and effective care it is clear that
low-value prescribing also incurs significant direct medi-
cation costs, totaling $21 million AUD to the govern-
ment in 2016. However, the majority of the cost of these
practices is likely to be related to their clinical adverse
effects [6]. For example, Table 3 illustrates how the cost
to the government of excess hip fractures related to
benzodiazepine use in the elderly may be in the region
of $29 million AUD annually. However, these potential
cost savings do not account for the additional costs of
alternative non-pharmacological treatments. This one
adverse drug event, when added to direct medicine costs
brings the total cost of benzodiazepine use in the elderly
to $41 million.
Implications for policy and future research
Our indicators of three low-value psychotropic prescrib-
ing practices have demonstrated a lack of any major
changes in their frequency, suggesting a more concerted
national effort is required to realize decreases in these
practices and their related harms. Part of this process
must be a deep understanding of the views of prescribers
and the pressures they experience as well as synthesizing
existing prescribing practice-specific intervention related
literature [26]. The indicators developed here could be
used to measure changes resulting from any ensuing in-
terventions. Knowledge of patient characteristics associ-
ated with these practices also provides some focus for
policy interventions. For instance, renewed efforts to tar-
get benzodiazepine and antipsychotic use in nursing
homes is likely to have the highest yield as an initial
approach as this population tends to be older and have
more co-morbidity [27–29].
Limitations
Private prescribing is not captured within PBS dispens-
ing claims and this is estimated to account for up to 10
and 6% of all benzodiazepine and antipsychotic pre-
scribing respectively [30]. We did not include z-drugs
in this study as they are not routinely captured in PBS
data and they only account for a small proportion of
sedative dispensings in Australia [30]. In this study we
were unable to capture dose reductions amongst indi-
viduals taking these medicines in attempts by pre-
scribers to minimise harm.
Medicines priced beneath the co-payment threshold
were not captured within PBS data prior to July 2012
but this unlikely to have affected our results [8]. We
made assumptions about the duration of exposure fol-
lowing one dispensing of a medicine in order to deter-
mine polypharmacy. Sensitivity analyses around these
assumptions, published elsewhere [10] demonstrate that
this is unlikely to affect trends but may underestimate
the true prevalence of antipsychotic polypharmacy. The
direct medicine costs of antipsychotic polypharmacy in-
cludes all antipsychotics involved in the polypharmacy
episode as without clinical details we were unable to
identify appropriate monotherapy. Therefore the cost of
antipsychotic polypharmacy will be an overestimate.
While the RxRisk score is predictive of mortality, it may
not capture all co-morbidities [31]. Past dispensings
claims for anti-dementia medicines only capture be-
tween 40 and 60% of people with dementia [32, 33],
therefore our primary indicator of this practice will most
likely under-estimate antipsychotic use in dementia. Ap-
plying the broader secondary indicator of people receiv-
ing new antipsychotic dispensings is likely to capture all
people using antipsychotics in the context of dementia
but may also capture antipsychotic use for other condi-
tions such as delirium. We used a three-year look-back
to identify past anti-dementia medicine dispensings, as
we believe that this will capture most people with a prior
dispensing of these medicines.
Finally, clinically contextual information such as the
indication for which the medicine was prescribed and
comorbidities was not available and hence we cannot be
certain that prescribing was inappropriate. However, we
have endeavored to quantify these three low-value prac-
tices as nominated by the Choosing Wisely campaign ra-
ther than to make judgments about the clinical
appropriateness of prescribing in each instance.
Conclusions
The ultimate aim of campaigns such as Choosing
Wisely is to optimize patient safety and quality of
Table 3 Calculation of downstream costs of benzodiazepine
use in the elderly related to hip fractures
Estimated adjusted rate ratio of hip fractures in elderly people
(≥50 years) taking benzodiazepines compared to those who were
not = 1.52 (95% CI: 1.37-1.68) [23]
Proportion of elderly people (≥65 years) dispensed benzodiazepines
(current study) = 0.067
Estimated number of osteoporotic & osteopenic hip fractures in
2016 = 26,232 [34]
Estimated average direct cost of a hip fracture in 2012 = $32,569
AUD [34]
Proportion of hip fractures attributable to benzodiazepines
¼ ð1:52−1Þ0:067½ð1:52−1Þ0:067Þþ1 ¼ 0:033
Number of hip fractures attributable to benzodiazepines
= 0.033*26,232 = 883
Excess costs of hip fractures related to benzodiazepine use in
the elderly
= 883*$32,569 = $29 million (95% CI: $20-$38 million) AUD
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care. The lack of any substantial change in indicators of
three low-value psychotropic prescribing practices de-
scribed here, along with their relatively high rates and po-
tential cost implications, indicates that renewed efforts
are required to achieve further decreases in the rates of
these practices.
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